Education
About Us
Working with TipRanks
Follow Us
Carlos Alban Insider Profile
11 Followers
Carlos Alban, Vice Chairman at AbbVie, holds 18.80K shares in Springworks Therapeutics (Ticker: SWTX), holds 155.34K shares in AbbVie (Ticker: ABBV), holds ― shares in Solventum Corporation (Ticker: SOLV).
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-14.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Carlos Alban holds in companies
Most Profitable Insider Trade
The most profitable trade made by Carlos Alban
Carlos Alban's Trading History
AbbVie
Nov 18, 2020
Vice Chairman
Uninformative Buy
4.16M
$33.29M
Springworks Therapeutics
May 17, 2024
Director
Uninformative Buy
―
$931.59K
Solventum Corporation
―
Director
―
―
Abbott Laboratories
Dec 04, 2012
SVP
Uninformative Buy
―
$18.67M
List of latest transactions for each holding click on a transaction to see Carlos Alban's performance on stock
You May Also Like
Carlos Alban insider profile FAQ
What is the percentage of profitable transactions made by Carlos Alban?
The percentage of profitable transactions made by Carlos Alban is 33%.
What is the average return per transaction made by Carlos Alban?
The average return per transaction made by Carlos Alban is -14.20%.
What stocks does Carlos Alban hold?
Carlos Alban holds: ABBV, SWTX, SOLV, ABT stocks.
What was Carlos Alban’s latest transaction?
Carlos Alban latest transaction was an Uninformative Buy of ―.
What was Carlos Alban's most profitable transaction?
Carlos Alban’s most profitable transaction was an Informative Sell of ABBV stock on March 2, 2018. The return on the trade was 27.20%.
What is Carlos Alban's role in AbbVie?
Carlos Alban's role in AbbVie is Vice Chairman.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.